Omega Therapeutics Inc. has presented preclinical data on hepatocyte nuclear factor 4-alpha (HNF4A) modulation in fibrotic liver disease models to enhance its key role and suggest it as a potent therapeutic target.

Genfit SA has highlighted its new focus and development strategy in acute-on-chronic liver failure (ACLF). The company's pipeline targets key pathophysiological pathways of ACLF, with priority given to systemic inflammation, cell death and microbiota.

Trex Bio Inc. has announced its selection of a new development candidate, TRB-061, designed to selectively agonize TNF receptor 2 (TNFR2), a mechanism with potential across a broad range of autoimmune indications.

Sosei Group Corp. and Kallyope Inc. have announced the successful identification, validation and nomination of a first G protein-coupled receptor (GPCR) target to enter a therapeutic discovery program for gastrointestinal (GI) diseases. The nominated target will advance into a structure-based drug discovery program.

It is well known that mutations in the cystic fibrosis transmembrane regulator (CFTR) gene are causative of cystic fibrosis, a lethal autosomal recessive Mendelian disorder. Several studies have also pointed to an association between CFTR mutations and inflammatory bowel disease (IBD).

F-box/WD repeat-containing protein 7 (FBXW7) is known to regulate the protein stability of key metabolic transcription factors, including the major transcriptional regulator of lipid biosynthesis, SREBP1, the overactivation of which has been previously linked to elevated lipogenesis.